Epigenetic events of disease progression in head and neck squamous cell carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 132, Issue 6, 2006, Pages 668-677

  Worsham, Maria J ^a   Chen, Kang Mei ^a   Meduri, Venkata ^a   Nygren, Anders O H ^b   Errami, Abdellatif ^b   Schouten, Jan P ^b   Benninger, Michael S ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b MRC HOLLAND   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; INTERLEUKIN 4; PROTEIN CDKN2; PROTEIN KLK10; PROTEIN P16; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; DISEASE COURSE; GENE AMPLIFICATION; GENE PROBE; GENE SILENCING; GENETIC ANALYSIS; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS; METHYLATION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CELL LINE; DISEASE PROGRESSION; DNA METHYLATION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED;

EID: 33745227364     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.132.6.668     Document Type: Article

References (52)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Costello JF, Plass C. Methylation matters. J Med Genet. 2001;38:285-303.
3. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 1992;69:915-926.
4. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 1993;366:362-365.
5. Pfeifer GP, Tanguay RL, Steigerwald SD, et al. In vivo footprint and methylation analysis by PCR-aided genomic sequencing: comparison of active and inactive X chromosomal DNA at the CpG island and promoter of human PGK-1. Genes Dev. 1990;4:1277-1287.
6. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000;24:132-138.
7. Issa JP, Vertino PM, Wu J, et al. Increased cytosine DNA- methyltransferase activity during colon cancer progression. J Natl Cancer Inst. 1993;85:1235-1240.
8. Lin SY, Yeh KT, Chen WT, et al. Promoter CpG methylation of caveolin-1 in sporadic colorectal cancer. Anticancer Res. 2004;24:1645-1650.
9. Smiraglia DJ, Smith LT, Lang JC, et al. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet. 2003;40:25-33.
10. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-167.
11. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
12. Chan MF, Liang G, Jones PA. Relationship between transcription and DNA methylation. Curr Top Microbiol Immunol. 2000;249:75-86.
13. Cairns P. Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Ann N Y Acad Sci. 2004;1022:40-43.
14. Kim H, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol. 2004;22:2363-2370.
15. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood. 2004;104:2492-2498.
16. Miracca EC, Kowalski LP, Nagai MA. High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer. 1999;81:677-683.
17. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-3229.
18. Rosas SL, Koch W, da Costa Carvalho MG, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001;61:939-942.
19. Hasegawa M, Nelson HH, Peters E, et al. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene. 2002;21:4231-4236.
20. Viswanathan M, Tsuchida N, Shanmugam G. Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer. 2003;105:41-46.
21. El-Naggar AK, Lai S, Clayman G, et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol. 1997;151:1767-1774.
22. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000;60:892-895.
23. Zou CP, Youssef EM, Zou CC, et al. Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta and on retinoid resistance in human squamous carcinoma cells. Oncogene. 2001;20:6820-6827.
24. Xu XC, Ro JY, Lee JS, et al. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res. 1994;54:3580-3587.
25. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990;50:6119-6129.
26. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333-339.
27. Nygren AO, Ameziane N, Duarte H, et al. Methylation-specific MLPA (MS-MLPA): detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005;33:e128.
28. Carey TE, Van Dyke DL, Worsham MJ, et al. Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UM-SCC-17A and UM-SCC-17B. Cancer Res. 1989;49:6098-6107.
29. Bradford CR, Kimmel KA, Van Dyke DL, et al. 11p deletions and breakpoints in squamous cell carcinoma: association with altered reactivity with the UM-E7 antibody. Genes Chromosomes Cancer. 1991;3:272-282.
30. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.
31. Worsham MJ, Pals G, Schouten JP, et al. Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:702-708.
32. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168-174.
33. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-428.
34. Maruya S, Issa JP, Weber RS, et al. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res. 2004;10:3825-3830.
35. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004;(157):327-349.
36. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant CpG island methylation of multiple genes in ependymal tumors. J Neurooncol. 2004;67:159-165.
37. Lee S, Hwang KS, Lee HJ, et al. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest. 2004;84:884-893.
38. Lomas J, Aminoso C, Gonzalez-Gomez P, et al. Methylation status of TP73 in meningiomas. Cancer Genet Cytogenet. 2004;148:148-151.
39. Luo LY, Rajpert-De Meyts ER, Jung K, et al. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer. 2001;85:220-224.
40. Dulaimi E, Ibanez de Caceres I, Uzzo RG, et al. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res. 2004;10:3972-3979.
41. Sarbia M, Geddert H, Klump B, et al. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer. 2004;111:224-228.
42. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 2000;60:5021-5026.
43. Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet. 2001;27:427-430.
44. Murakami Y, Nobukuni T, Tamura K, et al. Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci U S A. 1998;95:8153-8158.
45. Hui AB, Lo KW, Kwong J, et al. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog. 2003;38:170-178.
46. Ito T, Shimada Y, Hashimoto Y, et al. Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res. 2003;63:6320-6326.
47. Kwong J, Lo KW, To KF, et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res. 2002;8:131-137.
48. Brock MV, Gou M, Akiyama Y, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9:2912-2919.
49. Wong TS, Tang KC, Kwong DL, et al. Differential gene methylation in undifferentiated nasopharyngeal carcinoma. Int J Oncol. 2003;22:869-874.
50. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809-819.
51. Wittekind C. Prognostic factors in liver tumors [in German]. Verh Dtsch Ges Pathol. 1995;79:109-115.
52. Nomoto S, Haruki N, Kondo M, et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 1998;58:1380-1383.